

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|--------------------------------|--|--|----|-------|----------------|----------|-----------|
| 01 | Cefixime & Cloxacillin Extended Release Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 100 | mg | | |
| | | Cloxacillin Sodium Eq. to Cloxacillin (In Extended-Release Form) | IP | 500 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 02 | Cefixime & Cloxacillin Extended Release Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 200 | mg | | |
| | | Cloxacillin Sodium Eq. to Cloxacillin (In Extended-Release Form) | IP | 500 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 03 | Cefixime, Cloxacillin & Lactic Acid Bacillus Tablets | Each uncoated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 200 | mg | | |
| | | Cloxacillin Sodium Eq. to Cloxacillin | IP | 500 | mg | | |
| | | Lactic Acid Bacillus | | 90 | million spores | | |
| | | Excipients | | q.s. | | | |
| Approved colour used in tablet | | | | | | | |
| 04 | Cefixime & Dicloxacillin Extended-Release Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 200 | mg | | |
| | | Dicloxacillin Sodium Eq. to Dicloxacillin (In Extended-Release Form) | IP | 500 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 05 | Cefixime, Cloxacillin & Lactic Acid Bacillus Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 200 | mg | | |
| | | Cloxacillin Sodium Eq. to Cloxacillin (In Extended-Release Form) | IP | 500 | mg | | |
| | | Lactic Acid Bacillus | | 90 | million spores | | |
| | | Excipients | | q.s. | | | |
| Approved colour used in tablet | | | | | | | |
| 06 | Cefixime and Potassium Clavulanate Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to cefixime | IP | 50 | mg | | |
| | | Potassium clavulanate diluted Eq. to Clavulanic acid | IP | 31.25 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|--|--|----|------|----------------|----------|-----------|
| 07 | Cefpodoxime and Ofloxacin Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Anhydrous Cefpodoxime | IP | 100 | mg | | |
| | | Ofloxacin | IP | 100 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 08 | Cefixime and Potassium Clavulanate Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 100 | mg | | |
| | | Potassium clavulanate diluted Eq. to clavulanic acid | IP | 62.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 09 | Cefixime and Potassium Clavulanate Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 200 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 125 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 10 | Cefixime Tablets IP | Each uncoated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 50 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 11 | Cefixime Dispersible Tablets IP | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 50 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 12 | Cefixime Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 400 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 13 | Cefixime and Lactic Acid Bacillus Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Anhydrous Cefixime | IP | 100 | mg | | |
| | | Lactic Acid Bacillus | | 60 | million spores | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in coating | | | | | |
| 14 | Cefixime and Lactic Acid Bacillus Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefixime Eq. to Anhydrous Cefixime | IP | 200 | mg | | |
| | | Lactic Acid Bacillus | | 60 | million spores | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in coating | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|--|--|----|------|----------------|----------|-----------|
| 15 | Cefixime and Ofloxacin Dispersible Tablets | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefixime trihydrate Eq. to Cefixime | IP | 100 | mg | | |
| | | Ofloxacin | IP | 100 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 16 | Cefixime and Ofloxacin Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 100 | mg | | |
| | | Ofloxacin | IP | 100 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used | | | | | |
| 17 | Cefixime and Ofloxacin Dispersible Tablets | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefixime trihydrate Eq. to Cefixime | IP | 200 | mg | | |
| | | Ofloxacin | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 18 | Cefixime and Ofloxacin Sustained Release Tablets | Each film coated tablet contains: | | | | Our Self | |
| | | Cefixime trihydrate Eq. to Cefixime (As Sustained Release) | IP | 200 | mg | | |
| | | Ofloxacin (As Sustained Release) | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 19 | Cefixime, Ofloxacin & Lactic Acid Bacilus Tablets | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefixime trihydrate Eq. to Cefixime | IP | 200 | mg | | |
| | | Ofloxacin | IP | 200 | mg | | |
| | | Lactic Acid Bacillus | | 60 | million spores | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 20 | Cefixime and Ofloxacin Sustained Release Tablets | Each film coated tablet contains: | | | | Our Self | |
| | | Cefixime trihydrate Eq. to Cefixime (As Sustained Release) | IP | 400 | mg | | |
| | | Ofloxacin (As Sustained Release) | IP | 400 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 21 | Cefixime, Cloxacillin & Lactic Acid Bacillus Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 100 | mg | | |
| | | Cloxacillin Sodium Eq. to Cloxacillin (In Extended-Release Form) | IP | 500 | mg | | |
| | | Lactic Acid Bacillus | | 60 | million spores | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 22 | Cefixime, | Each film coated tablet contains:- | | | | Our Self | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|---|--|----|------|----------------|----------|-----------|
| | Azithromycin & Lactic Acid Bacillus Tablets | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 200 | mg | | |
| | | Azithromycin Dihydrate Eq. to Azithromycin Anhydrous | IP | 250 | mg | | |
| | | Lactic Acid Bacillus | | 60 | million spores | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet. | | | | | |
| 23 | Cefixime, Azithromycin & Lactic Acid Bacillus Tablets | Each uncoated tablet contains: - | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime Anhydrous | IP | 200 | mg | | |
| | | Azithromycin Dihydrate Eq. to Azithromycin Anhydrous | IP | 500 | mg | | |
| | | Lactic Acid Bacillus | | 60 | million spores | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet. | | | | | |
| 24 | Cefixime and Moxifloxacin Sustained Tablets | Each uncoated sustained release tablet contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime (As Sustained Release) | IP | 400 | mg | | |
| | | Moxifloxacin Hydrochloride Eq. to Moxifloxacin (As Sustained Release) | IP | 400 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 25 | Cefixime for Oral Suspension IP | Each 5ml after reconstitution contains: | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 50 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | Approved colour used | | | | | |
| 26 | Cefixime for Oral Suspension IP | Each 5ml after reconstitution contains: | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | IP | 100 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | Approved colour used | | | | | |
| 27 | Cefixime and Ofloxacin Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Anhydrous Cefixime | IP | 50 | mg | | |
| | | Ofloxacin | IP | 50 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| 28 | Cefixime and Ofloxacin Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Anhydrous Cefixime | IP | 100 | mg | | |
| | | Ofloxacin | IP | 100 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | | Mfg. for | Reference |
|---------|---|--|--|------|-------|----------------|----------|-----------|
| 29 | Cefixime and Ofloxacin Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Anhydrous Cefixime | | IP | 200 | mg | | |
| | | Ofloxacin | | IP | 200 | mg | | |
| | | In a palatable suspension base | | | q.s. | | | |
| 30 | Cefixime and Lactic Acid Bacillus Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | | IP | 50 | mg | | |
| | | Lactic Acid Bacillus | | | 60 | million spores | | |
| | | In a palatable suspension base | | q.s. | | | | |
| | | Approved colour used | | | | | | |
| 31 | Cefixime and Lactic Acid Bacillus Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | | IP | 100 | mg | | |
| | | Lactic Acid Bacillus | | | 60 | million spores | | |
| | | In a palatable suspension base | | q.s. | | | | |
| | | Approved colour used | | | | | | |
| 32 | Cefixime and Potassium Clavulanate Oral Suspension | Each 5ml reconstituted suspension contains: | | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | | IP | 50 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | | IP | 31.25 | mg | | |
| | | In a palatable suspension base | | | | | | |
| | | Approved colour used | | | | | | |
| 33 | Cefixime & Potassium Clavulanate Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | | IP | 100 | mg | | |
| | | Potassium clavulanate diluted Eq. to clavulanic acid | | IP | 28.5 | mg | | |
| | | Excipients | | | q.s. | | | |
| | | Approved colour used. | | | | | | |
| 34 | Cefixime and Potassium Clavulanate Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | | Our Self | |
| | | Cefixime Trihydrate Eq. to Cefixime | | IP | 100 | mg | | |
| | | Potassium clavulanate diluted Eq. to Clavulanic acid | | IP | 62.5 | mg | | |
| | | In a palatable suspension base | | | q.s. | | | |
| | | Approved colour used | | | | | | |
| 35 | Cefuroxime Axetil Tablets IP | Each Film coated tablet contains | | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | | IP | 250 | mg | | |
| | | Excipients | | | q.s. | | | |
| | | Approved colour used in tablet | | | | | | |
| 36 | Cefuroxime Axetil Tablets IP | Each Film coated tablet contains | | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | | IP | 500 | mg | | |
| | | Excipients | | | q.s. | | | |
| | | Approved colour used in tablet | | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|--|---|---------------|-----------------|---------------|---------------------|-----------|
| 37 | Cefuroxime Axetil and Potassium Clavulanate Tablets IP | Each film coated tablet contains | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 250 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 125 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 38 | Cefuroxime Axetil and Potassium Clavulanate Tablets IP | Each film coated tablet contains | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 500 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 125 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 39 | Cefuroxime & Potassium Clavulanate Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 125 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 28.5 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | Approved colour used. | | | | | |
| 40 | Cefuroxime & Potassium Clavulanate Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 250 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 57 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | Approved colour used. | | | | | |
| 41 | Cefuroxime Axetil and Potassium Clavulanate Oral Suspension | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 125 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 31.25 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | Approved colour used | | | | | |
| 42 | Cefuroxime Axetil and Potassium Clavulanate Tablets IP | Each film coated tablet contains | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 125 | mg | | |
| | | Potassium Clavulanate Diluted Eq to Clavulanic Acid | IP | 31.25 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 43 | Cefuroxime Axetil and Potassium Clavulanate Tablets IP | Each film coated tablet contains | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 250 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 62.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|---|--|----|-------|----|----------|-----------|
| 44 | Cefuroxime Axetil Oral Suspension | Each 5ml reconstituted suspension contains: | | | | Our Self | |
| | | Cefuroxime Axetil Eq. to Cefuroxime | IP | 125 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | Approved colour used | | | | | |
| 45 | Cefpodoxime and Potassium Clavulanate Dispersible Tablets | Each Uncoated Dispersible tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq to Anhydrous Cefpodoxime | IP | 50 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 31.25 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 46 | Cefpodoxime and Potassium Clavulanate Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefpodoxime proxetil Eq. to anhydrous cefpodoxime | IP | 100 | mg | | |
| | | Potassium clavulanate diluted Eq. to clavulanic acid | IP | 62.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 47 | Cefpodoxime and Potassium Clavulanate Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 100 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 62.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 48 | Cefpodoxime and Potassium Clavulanate Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Anhydrous Cefpodoxime | IP | 200 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 125 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 49 | Cefpodoxime Proxetil Dispersible Tablets | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 50 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 50 | Cefpodoxime Proxetil Dispersible Tablets 100 mg | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 100 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 51 | Cefpodoxime Tablets IP | Each Uncoated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 100 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|--|--|----|-------|----|----------|-----------|
| 52 | Cefpodoxime Tablets IP | Each Uncoated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 53 | Cefpodoxime Tablets IP | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 54 | Cefpodoxime Proxetil Dispersible Tablets | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 55 | Cefpodoxime Proxetil SR Tablets | Each Film coated sustained release tablet contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 56 | Cefpodoxime Proxetil SR Tablets | Each Film coated sustained release tablet contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 400 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 57 | Cefpodoxime & Potassium Clavulanate Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil IP Eq to Cefpodoxime | IP | 50 | mg | | |
| | | Potassium clavulanate diluted Eq. to clavulanic acid | IP | 28.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used. | | | | | |
| 58 | Cefpodoxime and Potassium Clavulanate Oral Suspension | Each 5ml reconstituted suspension contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Anhydrous Cefpodoxime | IP | 50 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 31.25 | mg | | |
| | | In a palatable suspension base | | | | | |
| | | Approved colour used | | | | | |
| 59 | Cefpodoxime & Potassium Clavulanate Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cefpodoxime Proxetil IP Eq to Cefpodoxime | IP | 100 | mg | | |
| | | Potassium clavulanate diluted Eq. to clavulanic acid | IP | 28.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used. | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST

PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|--|---|----|------|----|----------|-----------|
| 60 | Cefpodoxime & Dicloxacillin (ER) Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 100 | mg | | |
| | | Dicloxacillin Sodium Eq. to Dicloxacillin (As ER) | IP | 500 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 61 | Cefpodoxime & Dicloxacillin (ER) Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 200 | mg | | |
| | | Dicloxacillin Sodium Eq. to Dicloxacillin (As ER) | IP | 500 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 62 | Cefpodoxime and Ofloxacin Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 100 | mg | | |
| | | Ofloxacin | IP | 100 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 63 | Cefpodoxime and Ofloxacin Tablets | Each film coated tablet contains | | | | Our Self | |
| | | Cefpodoxime Proxetil Eq. to Cefpodoxime | IP | 200 | mg | | |
| | | Ofloxacin | IP | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 64 | Cephalexin Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cephalexin Eq. to Anhydrous Cephalexin | IP | 125 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 65 | Cephalexin Tablets IP | Each Uncoated tablet contains | | | | Our Self | |
| | | Cephalexin Eq. to Anhydrous Cephalexin | IP | 250 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 66 | Cephalexin Dispersible Tablets | Each uncoated dispersible tablet contains | | | | Our Self | |
| | | Cephalexin Eq. to Anhydrous Cephalexin | IP | 250 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 67 | Cephalexin Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cephalexin Eq. to Anhydrous Cephalexin | IP | 125 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | | | | | | |
| 68 | Cephalexin Oral Suspension IP | Each 5 ml of reconstituted suspension Contains: | | | | Our Self | |
| | | Cephalexin Eq. to Anhydrous Cephalexin | IP | 250 | mg | | |
| | | In a palatable suspension base | | q.s. | | | |
| | | | | | | | |

CEPHALOSPORINS TABLET, CAPSULE AND DRY SYRUP APPROVAL LIST
PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETICS RULE 1945

| Sr. No. | Generic Name / Brand Name | Composition | | | | Mfg. for | Reference |
|---------|--|--|-----|------|----|----------|-----------|
| 69 | Cefadroxil and Potassium Clavulanate Oral Suspension | Each 5 ml of reconstituted suspension contains | | | | Our Self | |
| | | Cefadroxil Monohydrate Eq. to Anhydrous Cefadroxil | IP | 250 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 62.5 | mg | | |
| | | In a palatable suspension base | | | | | |
| 70 | Cefadroxil and Potassium Clavulanate Dispersible Tablets | Each uncoated dispersible tablet contains: | | | | Our Self | |
| | | Cefadroxil Monohydrate Eq. to Anhydrous Cefadroxil | IP | 250 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 62.5 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 71 | Cefadroxil and Potassium Clavulanate Tablets | Each film coated tablet contains: | | | | Our Self | |
| | | Cefadroxil Monohydrate Eq. to Anhydrous Cefadroxil | IP | 500 | mg | | |
| | | Potassium Clavulanate Diluted Eq. to Clavulanic Acid | IP | 125 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 72 | Cefdinir Tablets | Each Film coated tablet Contains: | | | | Our Self | |
| | | Cefdinir | USP | 300 | mg | | |
| | | Excipients | | q.s | | | |
| | | Approved colour used | | | | | |
| 73 | Faropenem 200 mg Tablet | Each film coated tablet contains: | | | | Our Self | |
| | | Faropenem Sodium Eq. to Faropenem | | 200 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |
| 74 | Faropenem 300 mg Tablet | Each film coated tablet contains: | | | | Our Self | |
| | | Faropenem Sodium Eq. to Faropenem | | 300 | mg | | |
| | | Excipients | | q.s. | | | |
| | | Approved colour used in tablet | | | | | |